ONCOLOGY: LIQUID BIOPSY PRODUCTS | GLOBAL MARKETS

88 Pages | 35 Exhibits | 2018 Analysis | Forecasts Through 2022 Product Family: Market Reports




OVERVIEW:
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for liquid biopsy products.

ONCOLOGY MARKET HIGHLIGHTS

  • Total sales for liquid biopsy products are increasing rapidly as a result of a number of factors, including: the increasing prevalence of cancer, advances in sequencing and liquid biopsy technologies, and demand for alternatives to the current "gold standard," tissue biopsy.
  • In 2017, circulating tumor cell-based assays accounted for the largest share of total liquid biopsy products sales. However, during the forecast period (2017-22) circulating tumor DNA-based assays will become the largest biomarker segment in the liquid biopsy market due to the perceived benefits of ctDNA capture and analysis over other biomarkers.
  • The global market for liquid biopsy products is anticipated to increase at a CAGR of 27.2% during the forecast period, reaching approximately $2,036.25m in total product sales by 2022.
  • In 2017, North America was the largest region for liquid biopsy product sales, with an estimated market share of 46%. Europe was the second largest region in 2017; however, Meddevicetracker estimates that the Asia-Pacific region will surpass Europe in market share during this report's forecast period due to a rapid increase in test volume and large cancer burdens in these countries.
  • Extracellular vesicle/exosome-based assays will see the strongest growth out of all biomarker types.
Topics Covered Include:
  • An overview of liquid biopsy products used in the diagnosis and management of cancer patients for different clinical applications such as early disease detection, therapy selection (companion diagnostics), and response to therapy.
  • Global and region-specific market forecasts.
  • Forecasts by product segments.
  • Competitive analyses of industry leaders and disruptive new competitors.
  • Discussion of key drivers and limiters impacting the major product segments.
  • Primary research with oncologists and key opinion leaders from the US focused on how they are utilizing these assays and their preferred/most frequently utilized manufacturers.
  • A review of emerging technologies which could impact sales of existing assays.


TABLE OF CONTENTS:
Executive Summary
 
i. Cancer overview 
ii. Global liquid biopsy products market 
	a. Market drivers and limiters 
	b. Liquid biopsy products overview 
	c. Market trends 
	d. Market leaders 
	e. Competitive strategies 
	f. Emerging competition 
iii. Methodology 
iv. Bibliography 

Exhibit ES-1: Liquid biopsy products, global market forecast ($m), 2017-2022 
Exhibit ES-2: Global liquid biopsy products market, share by region, 2017 

1. Cancer Overview
 
1.1 Cancer prevalence and mortality 
1.2 Selected cancer statistics 
1.3 Cancer diagnostics 
1.4 Bibliography 

Exhibit 1-1: Age standardized cancer incidence and mortality cases (000s), 2012 
Exhibit 1-2: Highest age-standardized rates for all cancers, top 10 countries, 2012 
Exhibit 1-3: Age-standardized rates of cancer, select countries, 2012 
Exhibit 1-4: Estimated incidence of the five most common cancer types worldwide, 2012 
Exhibit 1-5: Estimated number of cancer deaths, select countries 
Exhibit 1-6: Estimated incident cases of blood cancers, United States, 2017 and 2027 
Exhibit 1-7: Estimated incident cases of blood cancers, Japan, 2017 and 2027 
Exhibit 1-8: Estimated incident cases of blood cancers, France, 2017 and 2027 
Exhibit 1-9: Estimated incident cases of blood cancers, Germany, 2017 and 2027 
Exhibit 1-10: Estimated incident cases of blood cancers, Italy, 2017 and 2027 
Exhibit 1-11: Estimated incident cases of blood cancers, Spain, 2017 and 2027 
Exhibit 1-12: Estimated incident cases of blood cancers, United Kingdom, 2017 and 2027 
Exhibit 1-13: Total estimated incident cases of blood cancers, select countries, 2017 and 2027 
Exhibit 1-14: Estimated incident cases of breast cancer, select countries, 2017 and 2027
Exhibit 1-15: Estimated incident cases of colorectal cancer, select countries, 2017 and 2027 
Exhibit 1-16: Estimated incident cases of NSCLC, select countries, 2017 and 2027 
Exhibit 1-17: Estimated incident cases of prostate cancer, select countries, 2017 and 2027 

2. Liquid Biopsy Products
 
2.1 Advantages and disadvantages of liquid biopsy 
2.2 Circulating tumor DNA assays 
	2.2.1 Companies and products 
2.3 Circulating tumor cell assays 
	2.3.1 Companies and products 
2.4 Extracellular vesicles and exosome assays 
	2.4.1 Companies and products 
2.5 Other biomarker tests 
2.6 Bibliography 

Exhibit 2-1: Advantages and disadvantages of liquid biopsy 
Exhibit 2-2: Selected ctDNA-based liquid biopsy assays 
Exhibit 2-3: Selected ctDNA-based sorting and isolation systems 
Exhibit 2-4: Selected CTC-based liquid biopsy assays 
Exhibit 2-5: Selected CTC sorting and isolation systems 

3. Liquid Biopsy Market
 
3.1 Global market insights 
	3.1.1 Market value 
	3.1.2 Trends in the liquid biopsy market 
	3.1.3 Market drivers and limiters 
	3.1.4 Liquid biopsy products overview 
	3.1.5 Market leaders 
	3.1.6 Competitive strategies 
	3.1.7 Emerging competition 
3.2 Competitors 
3.3 Primary Research 
3.4 Bibliography 

Exhibit 3-1: Liquid biopsy products, global market forecast ($m), 2017-2022 .
Exhibit 3-2: Liquid biopsy product sales, combined market forecast ($m), by product segment, 2017-22 
Exhibit 3-3: Global liquid biopsy products market, share by region, 2017 
Exhibit 3-4: Liquid biopsy product sales, US market forecast ($m), 2017-22 
Exhibit 3-5: Global liquid biopsy product sales, combined market forecast ($m) by region, 2017-22 
Exhibit 3-6: Selected mergers and acquisitions in the liquid biopsy market 
Exhibit 3-7: Selected fundraising milestones in the liquid biopsy market 
Exhibit 3-8: Selected liquid biopsy test costs 
Exhibit 3-9: Reported average number of liquid biopsies performed monthly - survey results 
Exhibit 3-10: Physician reported indications for liquid biopsy - survey results 
Exhibit 3-11: Physician reported disadvantages of liquid biopsy - survey results 

Appendix: Company Listing


COMPANIES COVERED:

  1. Agena Bioscience
  2. Agilent Genomics
  3. Amoy Diangostics
  4. ANGLE
  5. ApoCell
  6. Biocartis
  7. Biocept
  8. Biodesix
  9. BioFluidica
  10. Bio-Rad Laboratories
  11. Bio-Techne
  12. Boreal Genomics
  13. CellMax Life
  14. Chronix Biomedical
  15. Clearbridge BioMedics
  16. Cynvenio Biosystems
  17. Epic Sciences
  18. Exosome Diagnostics
  19. Exosome Sciences
  20. Exosomics Siena
  21. Epigenomics
  22. Fluxion Biosciences
  23. Foundation Medicine/Roche Diagnostics
  24. Freenome
  25. Genomic Health
  26. GILUPI
  27. GRAIL
  28. Guardant Health
  29. HansaBioMed Life Sciences
  30. Illumina
  31. Inivata
  32. Integrated Genetics/LabCorp
  33. Laboratory for Advanced Medicine
  34. MDxHealth
  35. Menarini Silicon Biosystems
  36. Myriad Genetics
  37. Natera
  38. NeoGenomics
  39. OncoCyte
  40. OncoDNA SA
  41. Pathway Genomics
  42. Personal Genome Diagnostics
  43. Precipio
  44. ProteoMediX
  45. Provista Diagnostics
  46. Qiagen
  47. RainDance Technologies/Bio-Rad Laboratories
  48. Roche Diagnostics/Hoffman-La Roche
  49. SeraCare
  50. Siemens Healthineers/Siemens
  51. Sysmex Inostics/Sysmex
  52. Swift Biosciences
  53. Thermo Fisher Scientific
  54. Trovagene
  55. Vortex Biosciences
Contact Us

Need help finding medtech research? Let us help you!